HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit an electronic Letter to the Editor about this paper Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (9) Citing Articles via Google Scholar Google Scholar Articles by Pagani, F. Articles by Waskiewicz, D. Search for Related Content PubMed PubMed Citation Articles by Pagani, F. Articles by Waskiewicz, D. Related Collections Proteomics and Protein Markers

Serum and Plasma Samples for ACS:Systems Cardiac Markers

¹ Laboratorio Analisi Chimico Cliniche 1, and,
² Cattedra e Divisione di Cardiologia, Azienda Ospedaliera ‘Spedali Civili’, and Universita’, 25125 Brescia, Italy
^a Author for correspondence. Fax 39-0303995369; e-mail panteghi@osp.unibs.it.

To The Editor:

The ACS:180^® immunoassay system (Bayer Diagnostics) is an automated random analyzer that uses acridinium ester-based chemiluminescence detection. The architecture of the cardiac marker assays is a heterologous sandwich format, using monoclonal anti-marker antibody immobilized onto paramagnetic particles (capture) and polyclonal goat anti-human myoglobin, creatine kinase MB isoenzyme (CK-MB), or cardiac troponin I (cTnI) antibody labeled with acridinium ester (detector). Its processing time (~20 min if the analyzer is in standby mode) and precision (overall CV <5%) make the system suitable for emergency use (1). However, optimal performance of an assay system for cardiac markers depends not only on the instrument’s analysis time, but also on factors that affect the overall turnaround time, including the preanalytical steps necessary to prepare the sample (2). The use of plasma samples eliminates the extra time needed for clotting, thereby reducing the overall preanalytical time, but there can be significant differences between serum and plasma concentrations of cardiac markers (3). The aim of this study was to validate the possible use of two different anticoagulants (lithium heparinate and EDTA, tripotassium salt) for cardiac marker determinations on the ACS:180 immunoassay system.

Twenty-five patients with acute myocardial infarction were studied. All gave informed consent. We collected three separate tubes (Sarstedt) to prepare serum, heparin plasma, and EDTA plasma in random order during one phlebotomy. ACS myoglobin, . . . [Full Text of this Article]

Acknowledgments

References

Barry Bluestein^3,a, Brian Markham³ and David Waskiewicz³

³ Cardiovascular Disease R&D, Lab Testing Segment, Bayer Corporation, 511 Benedict Ave., Tarrytown, NY 10591-5097
^a Author for correspondence.

To the Editor:

References

The following articles in journals at HighWire Press have cited this article:

				M. Panteghini and F. Pagani On the Comparison of Serum and Plasma Samples in Troponin Assays Clin. Chem., May 1, 2003; 49(5): 835 - 836. [Full Text]

				M. Panteghini Performance of Today's Cardiac Troponin Assays and Tomorrow's Clin. Chem., June 1, 2002; 48(6): 809 - 810. [Full Text] [PDF]